Publications Search

Search for publications by author
Search for publications by abstract keyword(s)

Search results

37 items matching your search terms.
Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue
Nguyen, L. T.; Lo, C. S.; Fyrsta, M.; Nie, J.; Yam, J. Y.; Yen, P. H.; Le, M. X.; Hersey, K.; Kenk, M.; Crumbaker, M.; Fleshner, N.; Kulkarni, G.; Hamilton, R.; Jewett, M.; Finelli, A.; Evans, A.; Sweet, J.; Ohashi, P. S.; Joshua, A. M.
Prostate Cancer 2022 :6499344, 2022 10.1155/2022/6499344
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)
Emmett, L.; Subramaniam, S.; Joshua, A. M.; Crumbaker, M.; Martin, A.; Zhang, A. Y.; Rana, N.; Langford, A.; Mitchell, J.; Yip, S.; Francis, R.; Hofman, M. S.; Sandhu, S.; Azad, A.; Gedye, C.; McJannett, M.; Stockler, M. R.; Davis, I. D.; Australian, New Zealand Urogenital Prostate Cancer Trials Group the Enza-p investigators
BJU International 2021 10.1111/bju.15491
Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase
Lin, H. M.; Mak, B.; Yeung, N.; Huynh, K.; Meikle, T. G.; Mellett, N. A.; Kwan, E. M.; Fettke, H.; Tran, B.; Davis, I. D.; Mahon, K. L.; Zhang, A.; Stockler, M. R.; Briscoe, K.; Marx, G.; Crumbaker, M.; Stricker, P. D.; Du, P.; Yu, J.; Jia, S.; Scheinberg, T.; Fitzpatrick, M.; Bonnitcha, P.; Sullivan, D. R.; Joshua, A. M.; Azad, A. A.; Butler, L. M.; Meikle, P. J.; Horvath, L. G.
EBioMedicine 72 :103625, 2021 10.1016/j.ebiom.2021.103625
Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer
Lin, H. M.; Yeung, N.; Hastings, J. F.; Croucher, D. R.; Huynh, K.; Meikle, T. G.; Mellett, N. A.; Kwan, E. M.; Davis, I. D.; Tran, B.; Mahon, K. L.; Zhang, A.; Stockler, M. R.; Briscoe, K.; Marx, G.; Bastick, P.; Crumbaker, M. L.; Joshua, A. M.; Azad, A. A.; Meikle, P. J.; Horvath, L. G.
Cancers 13 (19) :4964, 2021 10.3390/cancers13194964
UpFrontPSMA: a randomized phase 2 study of sequential (177) Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naive prostate cancer (clinical trial protocol)
Dhiantravan, N.; Emmett, L.; Joshua, A. M.; Pattison, D. A.; Francis, R. J.; Williams, S.; Sandhu, S.; Davis, I. D.; Vela, I.; Neha, N.; Bressel, M.; Murphy, D. G.; Hofman, M. S.; Azad, A. A.
BJU International 128 (3) :331-342, 2021 10.1111/bju.15384
PARP Inhibitors in Melanoma-An Expanding Therapeutic Option?
Chan, W. Y.; Brown, L. J.; Reid, L.; Joshua, A. M.
Cancers (Basel) 13 (18) :4520, 2021 10.3390/cancers13184520
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy
Sweeney, C. J.; Martin, A. J.; Stockler, M. R.; Begbie, S.; Chi, K. N.; Chowdhury, S.; Coskinas, X.; Frydenberg, M.; Hague, W. E.; Horvath, L. G.; Joshua, A. M.; Lawrence, N. J.; Marx, G. M.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S. A.; Parnis, F.; Parulekar, W.; Pook, D. W.; Reaume, M. N.; Sandhu, S. K.; Tan, A.; Tan, T. H.; Thomson, A.; Tu, E.; Vera-Badillo, F.; Williams, S. G.; Yip, S.; Zhang, A. Y.; Zielinski, R. R.; Davis, I. D.; Investigators, Enzamet Trial; the, Australian; New Zealand, Urogenital; Prostate Cancer Trials, Group
EUROPEAN UROLOGY 80 (3) :275-279, 2021 10.1016/j.eururo.2021.05.016
Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis
Wu, S. Z.; Roden, D. L.; Al-Eryani, G.; Bartonicek, N.; Harvey, K.; Cazet, A. S.; Chan, C. L.; Junankar, S.; Hui, M. N.; Millar, E. A.; Beretov, J.; Horvath, L.; Joshua, A. M.; Stricker, P.; Wilmott, J. S.; Quek, C.; Long, G. V.; Scolyer, R. A.; Yeung, B. Z.; Segara, D.; Mak, C.; Warrier, S.; Powell, J. E.; O'Toole, S.; Lim, E.; Swarbrick, A.
Genome Medicine 13 (1) :81, 2021 10.1186/s13073-021-00885-z
Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer
Kwan, E. M.; Fettke, H.; Crumbaker, M.; Docanto, M. M.; To, S. Q.; Bukczynska, P.; Mant, A.; Ng, N.; Foroughi, S.; Graham, L. K.; Haynes, A. M.; Azer, S.; Lim, L. E.; Segelov, E.; Mahon, K.; Davis, I. D.; Parente, P.; Pezaro, C.; Todenhofer, T.; Sathianathen, N.; Hauser, C.; Horvath, L. G.; Joshua, A. M.; Azad, A. A.
Translational Andrology and Urology 10 (4) :1688-1699, 2021 10.21037/tau-20-1444
Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies
Liang, Y.; Jeganathan, S.; Marastoni, S.; Sharp, A.; Figueiredo, I.; Marcellus, R.; Mawson, A.; Shalev, Z.; Pesic, A.; Sweet, J.; Guo, H.; Uehling, D.; Gurel, B.; Neeb, A.; He, H. H.; Montgomery, B.; Koritzinsky, M.; Oakes, S.; de Bono, J. S.; Gleave, M.; Zoubeidi, A.; Wouters, B. G.; Joshua, A. M.
CLINICAL CANCER RESEARCH 27 (8) :2340-2351, 2021 10.1158/1078-0432.CCR-20-3260
Ongoing partial response at 6 months to olaparib for metastatic melanoma with somatic PALB2 mutation after failure of immunotherapy: a case report
Lau, B.; Menzies, A. M.; Joshua, A. M.
Annals Of Oncology 32 (2) :280-282, 2021 10.1016/j.annonc.2020.11.006
Fats and Mets, KRAS-Driven Lipid Dysregulation Affects Metastatic Potential in Pancreatic Cancer
Man, J.; Pajic, M.; Joshua, A. M.
CANCER RESEARCH 80 (22) :4886-4887, 2020 10.1158/0008-5472.CAN-20-3082
OpenAccess publication Cancer patients' experiences with immune checkpoint modulators: A qualitative study
Ala-Leppilampi, K.; Baker, N. A.; McKillop, C.; Butler, M. O.; Siu, L. L.; Spreafico, A.; Abdul Razak, A. R.; Joshua, A. M.; Hogg, D.; Bedard, P. L.; Leighl, N.; Oza, A. M.; Parsons, J. A.; Hansen, A. R.
Cancer Medicine 9 (9) :3015-3022, 2020 10.1002/cam4.2940
OpenAccess publication The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis
Crumbaker, M.; Chan, E. K. F.; Gong, T.; Corcoran, N.; Jaratlerdsiri, W.; Lyons, R. J.; Haynes, A. M.; Kulidjian, A. A.; Kalsbeek, A. M. F.; Petersen, D. C.; Stricker, P. D.; Jamieson, C. A. M.; Croucher, P. I.; Hovens, C. M.; Joshua, A. M.; Hayes, V. M.
Cancers 12 (5) :1178, 2020 10.3390/cancers12051178
Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)
Scheinberg, T.; Kench, J.; Stockler, M.; Mahon, K. L.; Sebastian, L.; Stricker, P.; Joshua, A. M.; Woo, H.; Thanigasalam, R.; Ahmadi, N.; Centenera, M. M.; Butler, L. M.; Horvath, L. G.
BMJ Open 10 (1) :e033667, 2020 10.1136/bmjopen-2019-033667
Developing a pan-cancer research autopsy programme
Bavi, P.; Siva, M.; Abi-Saab, T.; Chadwick, D.; Dhani, N.; Butany, J.; Joshua, A. M.; Roehrl, M. H.
JOURNAL OF CLINICAL PATHOLOGY 72 (10) :689-695, 2019 10.1136/jclinpath-2019-205874